Cargando…
Quantification of EGFR mutations in primary and metastatic tumors in non-small cell lung cancer
BACKGROUND: EGFR mutation detection has been widely applied in the prediction of TKIs therapy in Non-Small Cell Lung Cancer (NSCLC). Metastatic tumors rather than primary tumors were usually assayed for those patients in advanced stages. Although the difference of EGFR mutation status in primary and...
Autores principales: | Wei, Bing, Yang, Ke, Zhao, Jiuzhou, Chang, Yuxi, Ma, Zihui, Dong, Bing, Guo, Yongjun, Ma, Jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3892091/ https://www.ncbi.nlm.nih.gov/pubmed/24398248 http://dx.doi.org/10.1186/1756-9966-33-5 |
Ejemplares similares
-
Different subtypes of EGFR exon19 mutation can affect prognosis of patients with non-small cell lung adenocarcinoma
por: Tian, Yingying, et al.
Publicado: (2018) -
Comprehensive analysis of aneuploidy status and its effect on the efficacy of EGFR-TKIs in lung cancer
por: Wei, Bing, et al.
Publicado: (2022) -
Real-world clinical treatment outcomes in Chinese non-small cell lung cancer with EGFR exon 20 insertion mutations
por: Shi, Chao, et al.
Publicado: (2022) -
Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real‐world clinical example
por: Wei, Bing, et al.
Publicado: (2019) -
Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs
por: Zhang, Chengjuan, et al.
Publicado: (2017)